

Table 1:

Radiopharmaceutical	Imaging Target	Cancer Site
Small Molecules (Imaging)		
[¹⁸ F]-FLT	tumor cell proliferation	lymphoma, prostate, H&N, NSCLC
[¹⁸ F]-FES	estrogen receptor status	breast
[¹⁸ F]-FDHT	androgen receptor	prostate
[¹⁸ F]-FMISO	tumor oxygenation	head & neck, rectal
[¹⁸ F]-FACBC	amino acid metabolism	breast, prostate, brain
[¹⁸ F]-FIAU	gene expression	prostate
[¹⁸ F]-ML10	imaging apoptosis	brain, NSCLC, H&N
[¹⁸ F]-FEAU	gene expression	all tumors and T cell therapies
[¹⁸ F]-dasatinib	tyrosine kinases	prostate, breast
[¹⁸ F]-glutamine	tumor metabolism	all solid malignancies
[⁶⁴ Cu]-ATSM	tumor oxygenation	uterine, cervical, rectal
[¹²⁴ I]-IAZGP	tumor oxygenation	rectal
[¹²⁴ I]-FIAU	gene expression	prostate
Na-[¹²⁴ I]	Na Iodide Symporter	thyroid
[¹²⁴ I]-PUH71	HSP-90	all solid malignancies and lymphoma
¹⁸ F-MFPG	hNET	neuroendocrine tumors
Antibodies and Fragments (Imaging)		
[⁶⁸ Ga]- Her2 F(ab')	HER2	breast
⁶⁴ Cu-DOTA-trastuzumab	HER2	breast
[¹²⁴ I]-A33	A33 antigen	colon
[¹²⁴ I]-3F8	disialoganglioside GD2	neuroblastoma (pediatrics)
[¹²⁴ I]-8H9	8H9 antigen	multiple tumors, e.g., leptomeninges (pediatrics)
[¹²⁴ I]-G250	CA9 antigen	renal
[⁸⁹ Zr]-DFO-huJ591	PSMA	prostate
[⁸⁹ Zr]-herceptin	herceptin	breast
¹¹¹ In-DOTA-cG250	CA9 antigen	renal
[⁸⁹ Zr]-DFO-MSTP2109A	PSMA	prostate
Antibodies and Fragments (Therapy)		
⁹⁰ Y-DOTA-cG250	CA9 antigen	renal
¹³¹ I-8H9	8H9 antigen	multiple tumors, e.g., leptomeninges (pediatrics)
¹³¹ I-3F8	disialoganglioside GD2	neuroblastoma (pediatrics)
²²⁵ Ac-lintuzumab	Anti-CD33	acute myeloid leukemia
Nanoparticles (Imaging)		
[¹²⁴ I]-Cdot nanoparticles	αvβ3	melanoma